Phase A — Understand the business
Lens 1 · Company Overview
Myriad Genetics is a ~38-year-old (Salt Lake City, Delaware-incorporated) molecular-diagnostics laboratory — it sells genetic tests, not drugs or instruments. Revenue is recognised when a test result is released to the provider/patient, and "consolidated revenues consist primarily of sales of genetic tests through our wholly-owned subsidiaries". It is the original BRCA company (the Myriad of AMP v. Myriad, the 2013 Supreme Court gene-patenting case) and still the only lab with an FDA-approved germline BRCA companion diagnostic (BRACAnalysis CDx).
FY2025 total revenue $824.5M, down 2% YoY ($837.6M FY2024; $753.2M FY2023). The product menu spans four historical lines, re-segmented into three care areas in Q1 2026:
- Hereditary Cancer — MyRisk (63-gene panel, 11+ cancer types; expanded Nov 2025) + BRACAnalysis CDx. FY25 $372.4M, 45% of revenue, +2% YoY.
- Tumor Profiling — Precise oncology, MRD pipeline. FY25 $121.7M, 15%, −3% YoY (dragged by the EndoPredict divestiture).
- Prenatal — Prequel NIPS, Foresight carrier screen, SneakPeek, the new FirstGene. FY25 $186.3M, 23%, +5%.
- Mental Health — GeneSight pharmacogenomics. FY25 $144.1M, 17%, −15% YoY.
Customers are payors and providers, not end consumers — and the single most important fact about this business is payor concentration risk: a coverage policy change by one insurer can vaporise a product line (see Lens 5/13). Total FY25 test volume 1,537k (+1%), so revenue softness is price/mix, not unit demand. Customers.csv is empty → no quantified payor concentration on the shelf, but the GeneSight/UnitedHealthcare episode below is the proxy.
Lens 2 · Supply Chain
This is a services/lab business, so the "supply chain" is reagents-in → lab-process → result-out → payor-reimburses, not a hardware BOM.
- Upstream inputs: laboratory reagents, consumables, and sequencing instruments/chemistry. The 10-K attributes FY25 cost-per-test reductions to "reductions in the cost of laboratory reagents and supplies". Sequencing chemistry is overwhelmingly an Illumina ecosystem dependency for NGS labs (industry structure; `` — not named in the filing). Myriad's CEO is himself ex-Illumina VP of Global Marketing (Lens 9), underscoring the platform reliance.
- The lab: wholly-owned CLIA labs (principal facility Salt Lake City, UT). PP&E net $114.0M; the company capitalises ~$11.8M/yr of internal-use software.
- Downstream "customer": the payor is the real counterparty. End demand comes from ordering physicians (oncologists, OB/GYNs, psychiatrists, PCPs), but cash comes from commercial insurers, Medicare/MolDx, and managed Medicaid. Reimbursement is the single chokepoint — coverage decisions and rate cuts are the supply-chain risk that matters.
- Named partners: SOPHiA GENETICS (Sept 2025 collaboration — global liquid-biopsy CDx for pharma); National Cancer Center Hospital East (Japan) (Precise MRD pan-cancer study partner); OrbiMed (lender, July 2025 term loan — see Lens 5/10).
- Chokepoints / single-source dependencies: (1) MolDx/Palmetto as the gatekeeper for Medicare coverage of new oncology tests — the entire MRD pipeline's commercial value hinges on it; (2) sequencing-instrument supplier concentration (Illumina); (3) third-party payor policy as a single point of failure for any one product (proved by GeneSight).
Lens 3 · Competitive Advantages (moats)
Myriad's moat is narrow, eroding, and concentrated in one franchise:
- Real, durable: Hereditary cancer brand + the only FDA-approved germline BRCA CDx. Two decades of clinical-utility data, medical-society guideline integration (MyRisk Management Tool), and ancestry-validated RiskScore. This is a genuine switching-cost/regulatory moat in germline hereditary cancer.
- Bargaining power — weak. Myriad needs the payors far more than they need Myriad; a single insurer (UnitedHealthcare) unilaterally cut GeneSight and erased ~$45M of revenue with no recourse. That is the definition of low bargaining power over customers.
- Where the moat is thin: everywhere outside germline hereditary cancer. In oncology MRD, prenatal NIPS, and pharmacogenomics, Myriad is a price-taking follower against far better-capitalised, faster-growing rivals (Lens 12/13). It has scale ($824M revenue, 1.5M tests/yr) but scale without growth or pricing power is not a moat.
- No network effect, modest IP edge post-AMP v. Myriad — the 2013 ruling stripped its gene-patent monopoly; today the moat rests on data + brand + the BRCA CDx label, not patents.
Net: Myriad owns a fortress in a shrinking castle (hereditary cancer) and is a tenant in every growth market it wants to enter (MRD).
Lens 4 · Segments
All (FY) and (Q1). No segment operating income is disclosed — Myriad reports revenue by category only, so EBIT-by-segment is n/a — not disclosed.
FY2025 revenue by category (old 4-way taxonomy):
| Category | FY25 $M | FY24 $M | YoY | % rev | Volume FY25 (k) | Vol YoY |
|---|
| Hereditary Cancer | 372.4 | 364.5 | +2% | 45% | 315 | +7% |
| Tumor Profiling | 121.7 | 125.8 | −3% | 15% | 48 | −9% |
| Prenatal | 186.3 | 177.1 | +5% | 23% | 637 | −4% |
| Mental Health | 144.1 | 170.2 | −15% | 17% | 537 | +6% |
| Total | 824.5 | 837.6 | −2% | 100% | 1,537 | +1% |
Q1 2026 revenue by category (new 3-way taxonomy):
| Category | Q1'26 $M | Q1'25 $M | YoY | % rev | Volume Q1'26 (k) | Vol YoY |
|---|
| Cancer Care Continuum | 120.2 | 115.6 | +4% | 60% | 96 | +13% |
| Prenatal Health | 41.9 | 49.3 | −15% | 21% | 153 | −12% |
| Mental Health | 38.3 | 31.0 | +24% | 19% | 136 | +7% |
| Total | 200.4 | 195.9 | +2% | 100% | 385 | 0% |
Trend & cause:
- Hereditary/Cancer Care = the anchor, slow-growing. +2% FY, accelerating to +4% in Q1 on +13% volume — but with an 8% decline in revenue-per-test in Q1, i.e. growing units by trading down on price. Quality-of-growth flag.
- Mental Health = the bleeding wound that's scabbing. −15% FY25 (the UnitedHealthcare GeneSight cut) but +24% in Q1 2026 as the company laps the cut and rebuilds direct-pay/coverage. The inflection is the single most encouraging data point in the print.
- Prenatal = decelerating, now declining. +5% FY but −15% in Q1 on a 12% volume drop (SneakPeek weakness). The FirstGene launch (2H 2026) is meant to reverse this.
- Geography: essentially all US. EndoPredict (Europe) was divested Aug 2024 and Myriad expects to discontinue EndoPredict in the US in 1H 2026 — Myriad is retreating to a US-only footprint.
Phase B — Measure performance
Lens 5 · Earnings Result (latest print: Q1 2026, reported 2026-05-05)
The headline: revenue scraped a beat-ish in-line, the bottom line is still deeply red, and management held guidance — but the company is burning cash and leaning on price/mix games.
Q1 2026 P&L:
- Revenue $200.4M, +2.3% YoY ($195.9M). Slightly below the ~$202.4M consensus.
- Gross profit $137.6M; gross margin 68.7% (vs 68.5% PY) — stable.
- Operating loss −$30.7M (widened from −$29.0M) — opex grew faster than revenue (S&M +6% to $73.6M).
- Net loss −$34.1M, EPS −$0.36 vs ~breakeven PY (PY had a one-time $29.3M tax benefit; ex-that, the underlying loss is comparable).
- Adjusted EPS loss ~$0.09, missing the ~$0.07 consensus loss.
- Interest expense jumped to $4.1M (from $0.8M) — the OrbiMed term loan now bites the P&L.
Balance-sheet flags:
- Cash $124.4M, down $25.2M in the quarter from $149.6M at YE25 — a ~$100M annualised burn pace on a $124M cash balance.
- Trade receivables rose to $123.8M (from $115.3M) while revenue was roughly flat — DSO creeping up against soft revenue is a working-capital watch item.
- Goodwill ground down again to $47.1M after another $5.4M impairment in Q1.
- Long-term debt $120.3M; no going-concern language in the 10-Q (solvency not flagged by management/auditor).
Guidance / outlook (reaffirmed): FY2026 revenue $860–880M, adj. gross margin 68–69%, adj. EBITDA $37–49M; H2 > H1, driven by FirstGene + MRD launches. The midpoint ($870M) implies ~5.5% growth — a return to growth after two flat-to-down years, but entirely back-half-loaded and product-launch-dependent.
Market reaction: muted-positive — the stock ticked +0.2% to ~$4.95 aftermarket / +2.9% on the day, better than its historically negative post-print reactions. Read: expectations are on the floor; an in-line print with a Mental Health inflection is enough to stop the bleeding.
Unusual vs own history: the +24% Mental Health rebound and +13% cancer volume are genuine positives; the −15% prenatal drop and the −8% cancer revenue-per-test are the offsets. The print is a "stabilising, not yet inflecting" quarter.
Lens 6 · Earnings Calls (sentiment trend)
No transcripts on the research shelf (transcripts/ empty) — sentiment is reconstructed ``. Tracking the arc from the 2025 collapse:
- Q1 2025 call (May 2025): crisis tone. Guidance cut on GeneSight/UNH and hereditary-cancer softness; stock fell 36% intraday. Management language: "re-accelerate volumes... will take time."
- JPM Jan 2026: strategic-reset tone. New CEO Raha reframes Myriad as cancer-focused, announces a menu refresh with five MRD tests over coming years. Pivot narrative replaces apology narrative.
- Q4 2025 / FY (Feb 2026): loss reiterated, 2026 outlook set; cost discipline emphasised (opex down across R&D/G&A FY25).
- Q1 2026 (May 2026): "mixed but stabilising." Reaffirmed guide, leaned on Precise MRD + FirstGene catalysts; Wolfe conference framed a "strategic shift in cancer care".
Shift over time: from damage-control (2025) → focused-pivot (2026). The recurring new phrases are "Precise MRD," "Cancer Care Continuum," "profitability," and "disciplined cost management." What they stopped saying: the broad four-vertical "comprehensive portfolio" framing — Mental Health and Women's Health are now de-emphasised (and impaired to near-zero goodwill). Tone is more credible than 2025 but still promissory: the catalysts are 2H-2026/2027 events.
Lens 7 · Comps
| Company | Ticker | Mkt cap (2026) | ~Revenue (2025) | EV/Sales | P/E | Div yld | 5y avg ROE |
|---|
| Myriad Genetics | MYGN | ~$0.40–0.56B | $824.5M FY25 | ~0.5–0.7x | neg (loss) | 0% | neg |
| Natera | NTRA | ~$27.4B | ~$2.06B FY25 | ~11–13x | neg | 0% | n/a |
| Exact Sciences | EXAS | ~$19.7B | $3.13–3.17B FY25 guide | ~6x | neg | 0% | n/a |
| Guardant Health | GH | ~$13.1B | $915–925M FY25 guide | ~14x | 0% | n/a | |
| Tempus AI | TEM | ~$9–10B | $1.265B FY25 guide | ~7–8x | 0% | n/a | |
| Veracyte | VCYT | ~$3.7B | ~$542M LTM ($582–592M FY26 guide) | ~6–7x | 0% | n/a | |
The single most important number in this dossier: SimplyWallSt puts MYGN at P/S ~0.5x vs a peer average ~5.6x. Myriad trades at a ~90% discount to its peer group on sales — because it is the only one with flat-to-declining revenue and no path to the 30–80% growth those multiples price. Cheapness is the thesis and the trap simultaneously: at <1x sales a credible return-to-growth re-rates the stock violently; continued decline justifies the discount.
Conflict to surface: market-cap quotes diverge by source/date — stockanalysis ~$560M (Jun 29), SimplyWallSt $393.6M / EV $459.4M (likely earlier in the month at a lower price). At 94.4M shares × ~$5.86 ≈ $553M mkt cap; with ~net-cash balance sheet, EV ≈ $0.45–0.55B. The range, not a false-precise point, is the honest read.
Lens 8 · Stock-Price Catalysts (moves >5%, ~5yr)
Mostly ``. The tape's verdict: this stock trades on payor-coverage news and guidance, not on science milestones.
- 2013 — AMP v. Myriad SCOTUS: gene-patent monopoly struck down; the original structural de-rating (historical context).
- 2024 (Sept) — 52-wk/multi-year high ~$28.60 on optimism about the menu + volume recovery.
- Late 2024 → 2025 — the collapse: the stock fell ~85% to the
$3.50–4.50 range, driven by UnitedHealthcare dropping GeneSight coverage ($45M revenue hit).
- 2025-05-07 — −36% in a session on the Q1'25 guidance cut.
- 2025-2026 — $319.4M goodwill/intangible impairment (Women's Health + Mental Health) drove the FY25 GAAP net loss to −$365.9M — confirmation, not cause, of the de-rating.
- 2026-05-05 — +2.9% on Q1'26 — first non-negative earnings reaction in a while; Mental Health inflection.
Pattern: the dominant share-price driver is reimbursement/payor policy (a single insurer can move the stock 30%+), with guidance revisions amplifying. Science/pipeline readouts (Precise MRD at ASCO/AACR) have moved the stock far less — the market won't pay for MRD until coverage (MolDx) is in hand. That makes the Q3-2026 MolDx submissions the real catalysts, not the conference data.
Phase C — Judge people & books
Lens 9 · Management
- CEO Samraat ("Sam") Raha (since 2025-04-30; joined as COO Dec 2023). Track record: 30+ yrs life-sciences/diagnostics — President of Agilent's Diagnostics & Genomics Group, VP Global Marketing at Illumina, GM of TaqMan/qPCR at Life Technologies. A professional operator with deep dx + sequencing pedigree — exactly the profile to run a reimbursement-and-menu turnaround. Not a founder; no large equity stake disclosed on the shelf (proxy-incorporated comp/ownership —
n/a from filings).
- Wholesale C-suite turnover in 2025: CFO Benjamin Wheeler (since 2025-08-16), COO Mark Verratti, CCO Brian Donnelly (2025-05-01) all new. A fresh-team reset — upside: no legacy baggage; risk: unproven as a unit, mid-turnaround.
- Capital-allocation history — mixed-to-poor. The prior regime overpaid for acquisitions now written off ($319.4M FY25 impairment in Women's Health + Mental Health; goodwill from $286.3M → $47.1M). They divested EndoPredict (2024) and are exiting US EndoPredict (2026) — sensible pruning. Funding via a high-cost OrbiMed term loan (10.4% rate) rather than equity at depressed prices is defensible but expensive. ROE is deeply negative (chronic losses); ROIC negative.
- Skin in the game / insider: director Daniel Skovronsky (Eli Lilly's Chief Scientific Officer) holds 195,507 shares — a notable strategic-pharma name on the board. Ownership is ~522 institutions / ~116.6M shares dominated by passive index funds (BlackRock, Vanguard, State Street, iShares S&P SmallCap) — i.e. orphaned small-cap with little active-conviction ownership.
- Red flags: the goodwill impairments are an indictment of prior M&A judgment, not the current team. No related-party or promotional-behaviour flags surfaced.
- Archetype: professional turnaround manager parachuted into a value-destruction situation. Right person; very hard job.
Lens 10 · Forensic Red Flags
Forensic-analyst lens. Every figure `` unless noted.
Accounting risk map (filings/10-k-2025-q4.md + 10-q-2026-q1.md):
- Revenue recognition — the #1 estimate risk, and the auditor agrees. Revenue is booked at an estimated collectible amount per test (variable consideration based on payor mix/historical collections). E&Y flagged "Measurement of revenue" as a Critical Audit Matter — it is "complex and judgmental". A lab that estimates what each payor will eventually pay can flatter or starve revenue via assumption changes. Watch the rising receivables vs flat revenue in Q1'26 (DSO creep) as the early-warning gauge.
- Goodwill/intangibles — largely cleaned out, but serial. $234.7M goodwill + $82.0M intangible impairment in FY25; second CAM was the goodwill impairment of Women's Health + Mental Health. Remaining goodwill is only $47.1M, so future impairment risk is now small — the damage is done, which is mildly de-risking going forward.
- Cash flow vs earnings divergence — the quietly important one. FY25 operating cash flow was +$1.8M, but that is flattered by a $27.5M draw-down of accrued liabilities and a non-cash tax-benefit reversal; "true" recurring cash generation is weak-to-negative. FY25 capex+capitalised-software $27.4M → FCF ≈ −$25.6M. Q1'26 burned $25.2M of cash. The earnings quality is low and the cash burn is real.
- SBC: $35.2M FY25 (4.3% of revenue), down from $49.8M FY24 — non-GAAP/adj-EBITDA flattering exists but is shrinking and modest by sector standards.
- Leases: sizeable operating-lease liabilities ($83.0M noncurrent) but standard.
- Debt covenant — the structural landmine. The OrbiMed facility carries a minimum TTM-revenue covenant starting at $615.0M (Dec-2025) and stepping to $974.0M by Dec-2029. Against $824.5M flat-to-declining revenue, the back-end steps (to $974M) require Myriad to grow revenue ~18% cumulatively into 2029 just to stay in compliance — exactly when the prior trend was negative. Compliant today; a multi-year tripwire if the MRD/FirstGene reacceleration fails. Interest rate 10.4%.
Regulatory findings (required sub-section) — read regulatory/regulatory-findings.md:
- SEC EDGAR EFTS (LR + AAER): zero Litigation Releases and zero AAERs naming Myriad Genetics, 2021-06-30 → 2026-06-30. No SEC accounting-fraud history.
- Item 3 / Note 10 (10-K): the only specifically disclosed litigation is the Ravgen patent suit (filed Dec 2020, blood-collection-tube/NIPT patents), settled Oct 2023 for $12.75M (a $21.3M expense reversal hit FY24 when a contingent payment was deemed no longer probable). Routine industry IP litigation, resolved.
- Non-SEC enforcement (web): material history of False Claims Act / anti-kickback settlements — $45.25M to DOJ + California + $2.75M to the whistleblower (2022, Vectra DA anti-kickback) and a $9.1M FCA qui tam settlement (2019). A securities class action (Bernstein Litowitz) reached settlement with distributions running through 2024-2025. These are historical and resolved, but they establish a pattern of reimbursement/kickback compliance exposure that fits a lab whose revenue depends on payor relationships.
- Verdict: clean on SEC accounting enforcement; not clean on healthcare-fraud/FCA history — the FCA settlements are the relevant regulatory scar. No active material enforcement found as of 2026-06-30.
Phase D — Project & stress-test
Lens 11 · Forward Projection (FY2026 / FY2027 / FY2028 EPS)
Built bottom-up from FY25 actuals + reaffirmed FY26 guidance. No forecast.ts logged (watchlist rule). All outputs ``; share count ~94.4M and rising ~1–2%/yr on SBC.
Anchors: FY25 revenue $824.5M, GAAP EPS −$3.95 (−$0.85 ex the $319.4M impairment ); FY26 guide revenue $860–880M, adj. EBITDA $37–49M. The company is GAAP-loss-making and will remain so through the window; the meaningful metric is adj. EBITDA → adj. EPS progression and the GAAP-breakeven date.
- Bear (no reacceleration; a payor or MRD setback): Revenue ~$840M FY26 (low end), flat-to-down FY27–28 as prenatal keeps sliding and MRD coverage slips. Adj. EBITDA ~$30M; GAAP EPS ≈ −$0.70 → −$0.65 → −$0.60. Covenant stress emerges by FY28–29.
- Base (guidance lands; modest reacceleration): FY26 ~$870M (+5.5%), FY27 ~$920M (+6%), FY28 ~$975M (+6%) as MRD early-access + FirstGene contribute and Mental Health stabilises. Adj. EBITDA $43M → $70M → $95M. GAAP EPS ≈ −$0.55 → −$0.30 → −$0.05 — approaching GAAP breakeven by ~FY2028. Adj. EPS turns slightly positive sooner (~FY27).
- Bull (MRD coverage + reacceleration to low-double-digits): FY26 $880M, FY27 ~$970M (+10%), FY28 ~$1.08B (+11%) as the 5-test MRD menu reimburses and Cancer Care compounds at 10%+. Adj. EBITDA $49M → $105M → $160M; GAAP EPS ≈ −$0.45 → −$0.05 → +$0.40 — GAAP-profitable by FY2028, and the covenant ($974M by 2029) is cleared with room.
Base call (for tracking, not logged): MYGN FY2027 non-GAAP EPS ≥ $0.00 — p≈0.45. The fulcrum is MolDx coverage for Precise MRD (Q3 2026 submissions) + FirstGene uptake; without coverage the MRD revenue is a 2027+ promise and the base/bull cases don't materialise.
Lens 12 · Bull vs Bear
Bull case. Myriad is a $824M-revenue, brand-leading molecular-dx franchise trading at ~0.5–0.7x sales while peers trade 6–14x — the cheapest name in a structurally growing category by an order of magnitude. The hereditary-cancer anchor (45% of revenue, the only FDA-approved germline BRCA CDx) is durable and growing volume; Mental Health has inflected (+24% in Q1); a credible new operating team (ex-Agilent/Illumina CEO) has pruned the portfolio, cut opex, and reframed the company around the secular MRD opportunity (five tumor-informed MRD tests, breast already in alpha launch, MolDx submissions in 2H-2026). If even the base guidance lands — return to ~5–6% growth and adj-EBITDA expansion toward GAAP breakeven by ~2028 — a re-rate from 0.6x toward even 2x sales is a multi-bagger off a $0.5B EV. The earnings surprise the market isn't pricing: MRD coverage + a stabilised Mental Health line simultaneously.
Bear case (permanent-impairment risks). (1) Payor concentration is an un-hedgeable structural risk — UnitedHealthcare unilaterally erased ~$45M of GeneSight revenue; any major payor can do the same to hereditary cancer or prenatal next, and Myriad has zero leverage to stop it. (2) It is a sub-scale follower in every growth market — Natera ($27B), Guardant ($13B), Tempus ($9B), Exact ($20B) outspend it 10–40x on R&D and commercial reach in exactly the MRD/liquid-biopsy arena Myriad is betting the turnaround on; arriving late and under-capitalised to the MRD party is the base-rate outcome. (3) Revenue has been flat-to-down for two years and the OrbiMed covenant steps to $974M by 2029 — if reacceleration fails, the company faces a covenant breach and a cash wall while burning ~$25M/quarter on a $124M balance. Pre-mortem (18 months out, thesis broke): MolDx coverage for Precise MRD slipped to 2027+, prenatal kept declining, a second payor trimmed hereditary-cancer rates, cash fell under $75M, and Myriad was forced into a dilutive equity raise at <$4 or a distressed refinancing — the "cheap" stock got cheaper because the revenue line never inflected. Are multiples too high? No — at 0.6x sales the multiple is not the risk; the denominator (revenue) and the balance sheet are. Contrarian view the market refuses to see: the market is treating Myriad as a structurally melting asset, but a focused, well-run hereditary-cancer cash franchise + a real (if late) MRD optionality at <1x sales is mispriced as a zero — the asymmetry is that the downside is partly in the price while the MRD/Mental-Health upside is free.
Lens 13 · Devil's Advocate (short-seller)
Dismantling the bull case.
- What structurally breaks the model: Myriad sells lab tests to payors who set the price and can drop coverage at will. Revenue is concentrated in two payor-sensitive lines (hereditary cancer 45–60%, prenatal 21%). A single coverage/rate decision — as UNH proved on GeneSight — can permanently impair a vertical. The model has no pricing power and no recurring lock-in.
- Most dangerous competitor bulls underestimate: Natera. It is the runaway leader in both of Myriad's growth ambitions — MRD (Signatera is the category-defining tumor-informed assay with broad MolDx coverage and reimbursement Myriad is only now applying for in Q3-2026) and women's health/NIPT (Panorama). Natera is ~$27B and growing 30–50%; Myriad's Precise MRD is launching into a market Natera already owns, years behind on coverage. Guardant (tissue-free MRD), Tempus (AI + sequencing scale), and Exact (Cologuard cash machine funding everything) compound the squeeze.
- Worst capital-allocation moves: the prior team destroyed ~$300M+ of acquired goodwill (now impaired) and the current team is funding the turnaround with 10.4% OrbiMed debt carrying a revenue covenant that escalates to $974M — borrowing expensively against a revenue line that has been shrinking.
- Assumptions that must hold for today's price: that revenue stops declining and reaccelerates to mid-single-digits, that MolDx grants Precise MRD coverage roughly on schedule, that no major payor trims hereditary-cancer/prenatal further, and that $124M cash + $75M undrawn is enough to reach cash-flow breakeven without a dilutive raise.
- If growth disappoints 20–30%: revenue ~$640–700M would breach the $615M→$974M covenant ladder, force a refinancing/raise at a depressed price, and the equity (EV ~$0.5B) could be substantially impaired or wiped in a restructuring — at which point 0.6x sales is not a floor.
- Single permanent-impairment scenario (and plausibility): a second major-payor coverage cut to hereditary cancer or prenatal, coincident with an MRD coverage delay — moderately plausible (payor-policy risk is recurring and proven; MRD coverage timing is genuinely uncertain). That combination turns a cheap turnaround into a value trap.
Lens 14 · Management Questions (ordered by information value)
- Precise MRD MolDx coverage: What is your base-case timeline and probability of Medicare/MolDx coverage for the breast MRD assay, and what is the contingency if the Q3-2026 submission slips to 2027? (This single answer most changes the thesis.)
- The OrbiMed covenant steps to $974M TTM revenue by Dec-2029 — at the current ~$825M base and your guided ~$870M, what specific revenue bridge gets you there, and what is your headroom/cure plan if a quarter misses?
- Cash fell to $124M and you burned ~$25M last quarter — what is your path to cash-flow breakeven, on what date, and what triggers a need to draw the $75M or raise equity?
- UnitedHealthcare erased ~$45M of GeneSight revenue overnight. What is your current single-largest-payor concentration in hereditary cancer and prenatal, and how are you de-risking another unilateral cut?
- Hereditary-cancer volume grew 13% but revenue-per-test fell 8% in Q1 — is this a deliberate share-grab or payor-driven price erosion, and where does ASP stabilise?
- You are entering MRD years behind Natera's Signatera on coverage and evidence. What is your right-to-win, and why won't you be a perennial price-following #4 in MRD?
- Mental Health rebounded +24% in Q1 after the UNH cut — how much is durable coverage recovery vs. direct-pay and easy comps, and what is the steady-state growth rate?
- Prenatal fell 15% on volume — does FirstGene reverse this in 2026, and what gives you confidence in the CONNECTOR readout and reimbursement path?
- With a new CFO, COO, and CCO all installed in 2025, what specifically is this team doing differently on capital allocation than the team that impaired $300M+ of goodwill?
- You divested EndoPredict and are exiting US EndoPredict — is further portfolio rationalisation (e.g. exiting a vertical entirely) on the table to concentrate cash on MRD?
- R&D is ~13% of revenue vs. multiples of that in absolute dollars at Natera/Tempus/Exact — how do you out-innovate on a fraction of the budget?
- What is the realistic peak-sales and gross-margin profile of the five-test MRD menu, and when does MRD become a material (>10% of revenue) contributor?
- Given the share price, have you evaluated strategic alternatives (sale of a vertical, whole-company combination), and what is the board's framework?
- The auditor flagged revenue measurement as a Critical Audit Matter — how should investors get comfort that estimated-collections revenue isn't being optimistically booked as receivables build?
- What are the two or three things that would make you conclude the cancer-focused turnaround is not working, and on what timeline would you act?